XGN Exagen Forecast, Technical & Fundamental Analysis
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand... Show more
XGN is expected to report earnings to rise 11.76% to -18 cents per share on August 10
Q2'26
Est.
$-0.19
Q1'26
Beat
by $0.05
Q4'25
Missed
by $0.01
Q3'25
Missed
by $0.15
Q2'25
Missed
by $0.06
The last earnings report on May 11 showed earnings per share of -17 cents, beating the estimate of -21 cents. With 128.72K shares outstanding, the current market capitalization sits at 100.26M.
A.I. Advisor
published General Information
General Information
a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases
A.I.dvisor tells us that XGN and QDEL have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XGN and QDEL's prices will move in lockstep.
Aroon Indicator for XGN shows an upward move is likely
XGN's Aroon Indicator triggered a bullish signal on June 10, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 166 similar instances where the Aroon Indicator showed a similar pattern. In of the 166 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XGN advanced for three days, in of 218 cases, the price rose further within the following month. The odds of a continued upward trend are .
XGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XGN as a result. In of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for XGN turned negative on June 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at .
XGN moved below its 50-day moving average on July 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.949) is normal, around the industry mean (12.988). P/E Ratio (0.000) is within average values for comparable stocks, (150.755). XGN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.632). XGN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.008). P/S Ratio (1.389) is also within normal values, averaging (7.587).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. XGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
